Medical complications during interhospital transfer for thrombectomy in patients with acute ischemic stroke.

Patients with acute ischemic stroke (AIS) and large-vessel occlusion are frequently transferred by emergency physicians (EPs) from primary to comprehensive stroke centers (CSC) for thrombectomy, particular when thrombolysed. Data on complications during such transfers are highly limited. Consecutive AIS patients transferred between 01/2015 and 10/2021 to our CSC were included. Associations of major (MACO) and minor (MICO) complications with clinical and imaging data were assessed. In total, 985 patients were included in the analysis (58.5% thrombolysed). MACO developed in 1.6%, MICO in 14.6%. Compared to patients without complications (NOCO), patients with MACO did not differ in terms of demographics, cerebrovascular risk factors, or site of vessel occlusion. They had more severe strokes ( In this large cohort, no patient-specific factor increasing the risk of complications during interhospital transfer was identified. Specifically, our results do not indicate that thrombolysis increases MACO. Hence, interhospital transfer without EPs appears reasonable in most patients.

Déclaration de conflit d'intérêts

Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Damjan Mirkov declares no conflicts of interest in relation to this work.Ekkehart Jenetzky declares no conflicts of interest in relation to this work.Andrea Thieme declares no conflicts of interest in relation to this work.Adeeb Qabalan declares no conflicts of interest in relation to this work.Christoph Gumbinger declares no conflicts of interest in relation to this work.Wolfgang Wick declares no conflicts of interest in relation to this work.Peter A. Ringleb received lecture honoraria from Boehringer Ingelheim, Bayer, PFIZER and Daiichi Sankyo and for advisory board activities from Boehringer Ingelheim and Pfizer not in relation to the topics of this publication.Timolaos Rizos received consulting honoraria, speakers’ honoraria and travel support from BMS Pfizer, Boehringer Ingelheim, Bayer HealthCare and Daiichi Sankyo, outside the submitted work.